New CEO commentary: “Fighting cancer with nanoparticles”
On PHI’s website, founder and CEO Peter Egelberg comments on a recently published scientific overview of the research results achieved by scientist in collaboration with the PHI – Northeastern University Program of Excellence for Quantitative Holographic Imaging, see http://www.phiab.se/commentary/commentary-170418.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.